Narjust Florez: It is not only about living longer but also living well for our patients
Narjust Florez shared a post by Shankar Siva, Professor, Faculty of Medicine at University of Melbourne on X/Twitter:
“When can we get it?
This will improve our patients schedule burden and risk for reactions.
It is not only about living longer but also living WELL for our patients. ”
Quoting Shankar Siva’s post:
“Lung cancer RCT of Subcutaneous versus I.V. Amivantamab (EGFR bispecific) in PALOMA-3 presented by Dr. Leigh’s ASCO24. Non-inferior for safety, efficacy + intriguing exploratory finding of increased OS with S/C delivery! Only 13% vs 66% infusion reaction with S/C delivery vs I.V.”
Source: Narjust Florez/X and Shankar Siva/X
Narjust Florez is the Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Brigham Cancer Center. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer.
She received the 2020 Rising Star award by the LEAD National Conference for women in hematology and oncology. In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine, and medical education.
